Surgical risk prediction for nasolacrimal duct obstruction in radioactive iodine treated thyroid cancer: A nationwide cohort study

Thyroid ◽  
2021 ◽  
Author(s):  
Ju-Yeun Lee ◽  
Kyung In Woo
Keyword(s):  
Cohort Study ◽  
Thyroid Cancer ◽  
Risk Prediction ◽  
Radioactive Iodine ◽  
Nasolacrimal Duct ◽  
Nasolacrimal Duct Obstruction ◽  
Surgical Risk ◽  
Duct Obstruction

Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer

2012 ◽  
Vol 33 (10) ◽  
pp. 1077-1080 ◽  
Author(s):  
Armaghan Fard-Esfahani ◽  
Saeed Farzanefar ◽  
Babak Fallahi ◽  
Davood Beiki ◽  
Mohsen Saghari ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Nasolacrimal Duct ◽  
Nasolacrimal Duct Obstruction ◽  
Duct Obstruction ◽  
Iodine 131

scholarly journals Secondary acquired nasolacrimal duct obstruction due to the toxic effect of antineoplastic agents

2021 ◽  
Vol 67 (6) ◽  
pp. 761-767
Author(s):  
Vasilii Iartsev ◽  
Evgeniia Atkova
Keyword(s):  
Toxic Effect ◽  
Radioactive Iodine ◽  
Nasolacrimal Duct ◽  
Chemotherapeutic Agents ◽  
Nasolacrimal Duct Obstruction ◽  
Antitumor Drugs ◽  
Antitumor Therapy ◽  
Preliminary Screening ◽  
Duct Obstruction ◽  
Timely Treatment

In recent years, the use of chemotherapeutic agents in the treatment of cancer became more common. At the same time, the number of complications associated with this is also increasing. Among the rare complications of therapy with some antitumor drugs is the formation of secondary acquired nasolacrimal duct obstruction. The aim was to analyze and systematize information about secondary acquired nasolacrimal duct obstruction due to the toxic effect of antitumor drugs. Materials and methods. The authors analyzed the literature available in the MEDLINE and RSCI search engines in February 2021. The analysis included 55 publications. Results. In the literature, there are indications that such antitumor drugs as 5-fluorouracil and similar drugs, mitomycin C, as well as therapy with radioactive iodine, are characterized by the possibility of developing complications in the form of secondary acquired nasolacrimal duct obstruction. Preliminary screening of the drainage function of the tear ducts, as well as prescribing of local anti-inflammatory and antibacterial treatment in the form of instillations in the conjunctival sac can help to reduce the risk of complications. This explains the need to recommend patients to consult an ophthalmologist if there are relevant complaints before or during treatment. In the absence of timely treatment, obstruction of the tear ducts often becomes an indication for reconstructive interventions. Conclusion. Secondary acquired nasolacrimal duct obstruction is one of the rare, but systematically occurring complications of antitumor therapy. To date, the pathogenesis of these complications is not fully understood, and some of the data is contradictory. In the future, the accumulation of knowledge concerning the pathogenesis of this complication will contribute to the development of personalized methods of prevention.

Nasolacrimal Duct Obstruction Associated With Radioactive Iodine Therapy for Thyroid Carcinoma

2003 ◽  
Vol 19 (6) ◽  
pp. 479-481 ◽  
Author(s):  
Todd R. Shepler ◽  
Steve I. Sherman ◽  
Misha-Michelle Faustina ◽  
Naifa L. Busaidy ◽  
M. Amir Ahmadi ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Nasolacrimal Duct ◽  
Nasolacrimal Duct Obstruction ◽  
Radioactive Iodine Therapy ◽  
Duct Obstruction
Sign in / Sign up

Export Citation Format

Share Document